A Simple Urine Screen Could Outsmart a Silent Killer

GDAŃSK, POLAND – June 10, 2026 – In a quiet but significant move that could reverberate through the global oncology landscape, Polish biotech firm Urteste S.A. has enrolled the first patient in a major clinical study for its Panuri test. This isn't just another incremental step in medical research; it's the clinical activation of a potentially revolutionary tool: a non-invasive urine test designed to detect pancreatic cancer, one of the world's most lethal and difficult-to-diagnose malignancies.

The announcement marks a critical transition from lab-based theory to real-world clinical evaluation. For a disease that often remains hidden until it’s too late for effective intervention, the prospect of a simple, affordable screening method represents a profound glimmer of hope. As the study gets underway across Europe, it places Urteste at the forefront of a crucial battle, where technological innovation meets a desperate, unmet medical need.

The Challenge of a Shadowy Disease

To grasp the significance of the Panuri test, one must first understand the grim reality of pancreatic cancer. It is a notoriously stealthy disease. Located deep within the abdomen, the pancreas can harbor a growing tumor for months or years without producing specific symptoms. By the time a patient experiences tell-tale signs like jaundice, weight loss, or abdominal pain, the cancer has often metastasized, drastically limiting treatment options.

The statistics are sobering. Pancreatic cancer is the seventh leading cause of cancer-related death globally, and its mortality rates are projected to rise, potentially making it the second deadliest cancer in the United States by 2030. The overall five-year survival rate languishes at a mere 13%. However, this bleak figure masks a critical detail: for the small fraction of patients whose cancer is caught at a localized, early stage, the five-year survival rate can leap to over 44%. Early detection is not just a benefit; it is the single most important factor determining a patient's chance of survival.

Current diagnostic tools are ill-suited for mass screening. Imaging like CT and MRI scans are expensive and often miss small, early-stage tumors. The most common blood marker, CA19-9, is notoriously unreliable, lacking the sensitivity and specificity needed for a standalone screening test. This diagnostic void leaves the general population unscreened and most patients diagnosed at an advanced stage, a reality that Urteste aims to fundamentally change.

The Science of Early Detection

Urteste's approach sidesteps the common methods of looking for cancer DNA in the blood. Instead, its proprietary technology focuses on a different biological signal: the activity of enzymes present in urine. The company’s innovative platform uses synthetic peptides to measure the activity of specific proteolytic enzymes that are closely linked to the early development of tumors. When these cancer-related enzymes are present, they interact with the test's reagents, causing a measurable change in the urine's color intensity.

This method holds several strategic advantages. It is entirely non-invasive, requiring only a simple urine sample, which dramatically lowers the barrier for patient compliance and frequent testing. According to the company, the test is also designed to be inexpensive and fast, with results potentially available in just a few hours.

The Panuri test, Urteste's flagship project, has already shown significant promise in its development phase. Preliminary data from R&D work, which formed the basis for the clinical trial design, indicated a sensitivity of 89% and a specificity of 75%. In diagnostics, sensitivity measures the test's ability to correctly identify those with the disease, while specificity measures its ability to correctly identify those without it. While these figures will need to be validated in the current, larger clinical study, they represent a compelling starting point that has already captured the interest of potential strategic partners.

From Lab to a Multi-Country Clinical Trial

The launch of patient enrollment moves the Panuri test from a promising concept to a rigorously evaluated medical device. The study is a significant logistical undertaking, designed to be multicenter and multinational, spanning 30 sites across Poland, Hungary, and Italy. This international scope is crucial for gathering data from a diverse patient population, strengthening the eventual regulatory submission.

The trial will involve 550 participants, split between a target group of patients with symptoms suggestive of pancreatic cancer and an "enriched" group of patients already scheduled for pancreatic evaluation. This design will allow researchers to assess the test’s primary endpoints—its sensitivity and specificity—in a clinically relevant setting.

Urteste has assembled a team of experienced international partners to execute the study. The Finnish group Aurevia is managing the trial as the Contract Research Organization (CRO), while the German company Biotype is responsible for manufacturing the test kits as a Contract Development and Manufacturing Organization (CDMO).

"Enrolling the first patient in a clinical study using the Panuri test is an important step toward commercialization for us," stated Grzegorz Stefański, co-founder and CEO of Urteste S.A., in the company's press release. "We anticipate a smooth recruitment process and expect the first interim analysis results by the end of the year. Obtaining positive results will significantly increase the likelihood of entering into a partnership agreement."

The Strategic Horizon and a Broader Vision

For Urteste, a publicly traded company on the Warsaw Stock Exchange (URT), the Panuri trial is a pivotal moment. Positive interim results, expected in the fourth quarter of this year, would not only de-risk the project significantly but also serve as a powerful validation of the company's entire technology platform. It would be a major catalyst for the partnership discussions that are already underway.

The competitive landscape for non-invasive diagnostics is fierce, with many companies pursuing blood-based "liquid biopsies." Urteste's focus on urine and enzyme activity offers a differentiated approach that could carve out a significant niche, particularly if it proves to be more cost-effective and easier to deploy at scale.

Moreover, Panuri is just the tip of the iceberg. The company has a deep pipeline of 13 prototype tests targeting other major cancers, including breast, lung, and prostate cancer, which collectively account for a vast portion of global cancer mortality. Success with Panuri would provide a powerful proof-of-concept for this broader platform, potentially positioning Urteste as a major player in the future of preventative medicine.

The study's results will be a cornerstone of the documentation for CE mark certification in Europe under the stringent In Vitro Diagnostic Regulation (IVDR). The company is also engaged with the U.S. Food and Drug Administration (FDA), and the data may supplement a future clinical study in the United States, opening the door to the world's largest healthcare market. As the first patient's sample is analyzed, it represents more than just a data point; it's the start of a journey that could transform the diagnosis of a deadly disease and redefine the value of early detection.